secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002661
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra reports BEACON Phase 2 smell-loss data: 0.87 improvement at week 24 (p=0.026)
--------------------------------------------------------------------------------

- BEACON Phase 2 trial: 0.87 improvement in smell loss vs control at week 24 (p=0.026) in patients with impaired smell at baseline.
- Data filed in corporate presentation posted Jan 8, 2024; subset analysis shows statistically significant benefit.
- No safety or additional efficacy details disclosed; further development plans not specified.
- Lyra is a clinical-stage biotech focused on chronic rhinosinusitis therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024002661/0000950170-24-002661-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017024002661/lyra-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002661

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer